Otsuka Holdings Co.,Ltd. FY2026 Q1 Earnings Report

Quick View

Executive Summary

While revenue growth continued, the profit margin of the core business declined, and the increase in net income was primarily driven by an improvement in financial income and expenses. Revenue was ¥6,303.4B (+8.2% YoY), operating income was ¥1,262.9B (+1.5%), profit before tax was ¥1,302.3B (+14.9%), and net income attributable to owners of the parent was ¥983.5B (+15.7%). Although cost of sales and SG&A expenses increased at a faster pace than revenue, causing the operating margin to decline to 20.0% from 21.3% in the same period last year, the decrease in financial expenses boosted profit before tax and net income.

Factors Affecting Performance

【Revenue】Revenue increased across all reported segments. The Medical-Related Business led growth, with revenue of ¥4,538.2B (+8.6%), accounting for 72.0% of consolidated revenue. The Nutraceutical-Related Business generated ¥1,389.2B (+5.8%), the Consumer-Related Business generated ¥79.2B (+7.3%), and Other Businesses generated ¥296.8B (+12.9%), with all segments recording higher revenue.

【Profit and Loss】Consolidated operating income was limited to ¥1,262.9B (+1.5%), indicating weak operating leverage relative to revenue growth of 8.2%. The core Medical-Related Business recorded segment profit of ¥1,155.0B (-0.9%) and a profit margin of 25.4% (-2.5pt YoY), making it the primary cause of the decline in the consolidated profit margin. Meanwhile, the substantial decrease in financial expenses from ¥137.5B to ¥20.4B supported growth in profit before tax and net income. Cost of sales increased by +11.1% and SG&A expenses by +11.6%, both exceeding revenue growth, indicating a decline in cost absorption capacity. In conclusion, while the operating level showed a slowdown characterized by higher revenue but lower profit, net income increased due to non-operating factors.

Segment Analysis

The Medical-Related Business is the core business, with revenue of ¥4,538.2B (+8.6%), profit of ¥1,155.0B (-0.9%), and a profit margin of 25.4% (-2.5pt YoY), accounting for 82.6% of total reported segment profit. The Nutraceutical-Related Business recorded revenue of ¥1,389.2B (+5.8%), profit of ¥157.8B (+1.3%), and a profit margin of 11.4% (-0.5pt), representing a slight decline. The Consumer-Related Business maintained high profitability, with revenue of ¥79.2B (+7.3%), profit of ¥56.4B (+8.7%), and a profit margin of 71.3% (+0.9pt). Other Businesses improved, with revenue of ¥296.8B (+12.9%), profit of ¥29.2B (+62.6%), and a profit margin of 9.9% (+3.2pt). Consolidation adjustments amounted to -¥135.6B, primarily due to ¥155.2B in unallocated corporate expenses. The structure is clear: the decline in the Medical-Related Business profit margin is weighing down the consolidated operating margin.

Key Financial Indicators

【Profitability】The operating margin declined by 1.3pt to 20.0% from 21.3% in the same period last year, while the net profit margin improved by 1.0pt to 15.6% from 14.6%. The gross margin declined slightly to 72.4% from 73.1%. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥1,088.8B, equivalent to 1.11 times net income, indicating sound cash support for earnings. 【Investment Efficiency】Annualized ROE was 12.5%, achieved under a conservative capital structure with an equity ratio of 73.8%. EPS was ¥186.31 (+17.5%), while BPS was ¥5,894.25. 【Financial Soundness】Current assets of ¥16,002.4B substantially exceeded current liabilities of ¥6,861.2B, resulting in a high current ratio of 233.2%. Total bonds and borrowings of ¥948.2B were substantially below cash of ¥5,383.0B, indicating a sound financial base.

Cash Flow Analysis

Operating Cash Flow (OCF) was ¥1,088.8B (+3.3% YoY), equivalent to 1.11 times net income, indicating strong cash conversion of earnings. In terms of working capital, the decrease in trade receivables generated a cash inflow of ¥386.7B, while an increase in inventories of ¥135.0B and a decrease in trade payables of ¥253.6B were sources of cash outflow. Investing Cash Flow (ICF) was -¥224.0B, of which capital expenditures accounted for ¥251.6B. Financing Cash Flow (FCF) was -¥846.2B and included dividend payments of ¥375.0B, share repurchases of ¥84.4B, and bond redemptions of ¥300.0B. Free cash flow after capital expenditures was ¥864.9B, comfortably exceeding the combined ¥459.4B in dividend payments and share repurchases, indicating strong coverage of shareholder returns by internally generated funds.

Quality of Earnings

Operating income of ¥1,262.9B included ¥83.6B in equity-method investment income and ¥43.3B in other income. Outside operating income, financial income of ¥59.8B less financial expenses of ¥20.4B resulted in a positive contribution of ¥39.4B. In the same period last year, financial expenses were a significant burden at ¥137.5B. Accordingly, the primary driver of growth in profit before tax and net income was the improvement in financial income and expenses, which differs qualitatively from core operating income growth of +1.5%. Net income attributable to owners of the parent was ¥983.5B against profit before tax of ¥1,302.3B, reflecting income taxes of ¥309.3B and an effective tax rate of 23.8%. Although OCF was 1.11 times net income, providing sound cash support, the fact that an improvement in financial income and expenses—a temporary factor dependent on market conditions—led the improvement in net income should be considered when evaluating earnings quality.

Earnings Forecast and Guidance

The full-year company plan calls for revenue of ¥25,200B, operating income of ¥3,600B (-24.9% YoY), and net income of ¥2,690B (-27.0%), implying a plan for a substantial full-year earnings decline. The Q1 progress rate was 25.0% for revenue, which is broadly standard, while operating income and net income reached 35.1% and 37.1%, respectively, both substantially exceeding the simple 25% progress benchmark. This indicates that the improvement in financial income and expenses in Q1 is running ahead of the planned full-year earnings decline scenario, and progress may normalize in subsequent quarters due to higher costs or changes in the financial environment. No revisions have been made to the earnings or dividend forecasts.

Shareholder Returns

Dividend payments during Q1 amounted to ¥375.0B, resulting in a payout ratio of 38.1% against net income attributable to owners of the parent of ¥983.5B. Including share repurchases of ¥84.4B, total shareholder returns amounted to ¥459.4B, resulting in a Total Return Ratio of 46.7%. Free cash flow of ¥864.9B was 2.31 times dividend payments and 1.88 times total shareholder returns, indicating that shareholder returns are adequately covered by internally generated funds. The full-year dividend forecast is ¥140 per share, implying a forecast payout ratio of 27.7% based on forecast full-year EPS of ¥504.94.

Risk Factors

1. Inventory accumulation risk: Inventories increased by +4.1% from the end of the previous fiscal year to ¥3,896.8B, and inventory days are substantially above the cautionary level. Even considering the company’s diversified business characteristics, including pharmaceuticals and beverages, it is necessary to monitor the risk of demand forecast errors and inventory write-downs.

2. Declining profit margin in the core business: The Medical-Related Business, which accounts for 82.6% of consolidated profit, recorded profit of -0.9% despite revenue growth of +8.6%, while its profit margin declined to 25.4% (-2.5pt YoY). The cost structure and changes in product mix in the core business directly affect consolidated earnings power.

3. Dependence on improved financial income and expenses: The increase in net income was primarily attributable to the decline in financial expenses from ¥137.5B to ¥20.4B, a factor separate from core operating income growth of +1.5%. Changes in market conditions may impair the reproducibility of the improvement in financial income and expenses.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Absolute comparative benchmark data for the company’s operating and net profit margins within the industry is limited, and the comparison is therefore restricted to a standalone horizontal comparison of the company.

Growth and Capital Efficiency

Revenue growth of 8.2% is a solid level, although comparative data against the industry median is limited.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Revenue increased across all reported segments, and the full-year revenue progress rate was also 25.0%, in line with the plan. However, the operating margin declined by 1.3pt from the previous year, indicating a change in cost absorption capacity.

2. OCF was 1.11 times net income, and free cash flow of ¥864.9B exceeded total shareholder returns of ¥459.4B, indicating sound cash support for earnings and strong capacity for shareholder returns.

3. Against a conservative financial structure represented by an equity ratio of 73.8% and a current ratio of 233.2%, the increase in inventory days and the profit margin trend of the core Medical-Related Business will be key areas to monitor when evaluating future profitability.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥5,835–¥6,184 at ±1% for the cost of equity, and ¥6,003–¥6,010 at ±0.1 for ω.

Notes:

• Because net income progress against the full-year forecast (37%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies running ahead of plan tend to exceed forecasts. In businesses with strong seasonality, the adjustment may be excessive).
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market stock price or a recommendation of any specific investment action, and does not predict or guarantee the future stock price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings report data. It does not recommend investment in any specific issue. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---